BIONTECH SE-ADR (22UA.DE) Stock Price & Overview
FRA:22UA • US09075V1026
The current stock price of 22UA.DE is 86.7 EUR. Today 22UA.DE is down by -0.74%. In the past month the price decreased by -4.64%. In the past year, price decreased by -14.03%.
22UA.DE Key Statistics
- Market Cap
- 20.847B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.37
- Dividend Yield
- N/A
22UA.DE Stock Performance
22UA.DE Stock Chart
22UA.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 22UA.DE. When comparing the yearly performance of all stocks, 22UA.DE is a bad performer in the overall market: 78.01% of all stocks are doing better.
22UA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 22UA.DE. While 22UA.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
22UA.DE Earnings
On November 3, 2025 22UA.DE reported an EPS of -0.12 and a revenue of 1.52B. The company beat EPS expectations (44.42% surprise) and beat revenue expectations (55.06% surprise).
22UA.DE Forecast & Estimates
28 analysts have analysed 22UA.DE and the average price target is 118.89 EUR. This implies a price increase of 37.13% is expected in the next year compared to the current price of 86.7.
For the next year, analysts expect an EPS growth of -19.54% and a revenue growth 4.52% for 22UA.DE
22UA.DE Groups
Sector & Classification
22UA.DE Financial Highlights
Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -2.37. The EPS decreased by -20.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| Debt/Equity | 0.01 |
22UA.DE Ownership
22UA.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.21 | 40.274B | ||
| ARGX | ARGENX SE | 25.36 | 40.187B | ||
| ABVX | ABIVAX SA | N/A | 7.876B | ||
| 2X1 | ABIVAX SA | N/A | 7.852B | ||
| GLPG | GALAPAGOS NV | N/A | 1.906B | ||
| GXE | GALAPAGOS NV | N/A | 1.904B | ||
| NANO | NANOBIOTIX | N/A | 1.311B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.096B | ||
| PHIL | PHILOGEN SPA | 16.57 | 616.964M | ||
| GNFT | GENFIT | N/A | 444.526M | ||
| AYJ | VALNEVA SE | N/A | 402.324M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 22UA.DE
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ DE
Employees: 6772
Phone: 4949613190840
BIONTECH SE-ADR / 22UA.DE FAQ
What does BIONTECH SE-ADR do?
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
What is the current price of 22UA stock?
The current stock price of 22UA.DE is 86.7 EUR. The price decreased by -0.74% in the last trading session.
What is the dividend status of BIONTECH SE-ADR?
22UA.DE does not pay a dividend.
What is the ChartMill rating of BIONTECH SE-ADR stock?
22UA.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is BIONTECH SE-ADR (22UA.DE) stock traded?
22UA.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the market capitalization of 22UA stock?
BIONTECH SE-ADR (22UA.DE) has a market capitalization of 20.85B EUR. This makes 22UA.DE a Large Cap stock.
Can you provide the upcoming earnings date for BIONTECH SE-ADR?
BIONTECH SE-ADR (22UA.DE) will report earnings on 2026-03-10, after the market close.